CN1116928A - 眼用组合物 - Google Patents

眼用组合物 Download PDF

Info

Publication number
CN1116928A
CN1116928A CN95100372A CN95100372A CN1116928A CN 1116928 A CN1116928 A CN 1116928A CN 95100372 A CN95100372 A CN 95100372A CN 95100372 A CN95100372 A CN 95100372A CN 1116928 A CN1116928 A CN 1116928A
Authority
CN
China
Prior art keywords
group
randomly substituted
dihydro
hydroxyl
intraocular pressure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN95100372A
Other languages
English (en)
Chinese (zh)
Inventor
小河贵裕
出口敬章
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Publication of CN1116928A publication Critical patent/CN1116928A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN95100372A 1994-01-27 1995-01-27 眼用组合物 Pending CN1116928A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP7470/94 1994-01-27
JP747094 1994-01-27

Publications (1)

Publication Number Publication Date
CN1116928A true CN1116928A (zh) 1996-02-21

Family

ID=11666688

Family Applications (1)

Application Number Title Priority Date Filing Date
CN95100372A Pending CN1116928A (zh) 1994-01-27 1995-01-27 眼用组合物

Country Status (9)

Country Link
US (1) US5538974A (https=)
EP (1) EP0667156B1 (https=)
KR (1) KR950032169A (https=)
CN (1) CN1116928A (https=)
AT (1) ATE157870T1 (https=)
CA (1) CA2141176A1 (https=)
DE (1) DE69500660T2 (https=)
ES (1) ES2106573T3 (https=)
TW (1) TW316235B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102548548A (zh) * 2009-06-10 2012-07-04 米拓科技有限责任公司 用于医学和兽医学的眼科药物组合物
CN114767688A (zh) * 2019-09-04 2022-07-22 武汉科福新药有限责任公司 透皮促渗组合物及其在噻吗洛尔制剂中的应用

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
CN1269484C (zh) 1998-09-18 2006-08-16 艾尔科实验室公司 用于治疗青光眼的5－羟色胺激活性激动剂
US6903081B2 (en) * 2000-03-31 2005-06-07 Purdue Research Foundation Phosphoramidates and methods therefor
FR2822467B1 (fr) * 2001-03-22 2003-12-12 Pf Medicament Derives benzoxathiepines et leur utilisation comme medicaments
WO2003051352A1 (en) * 2001-12-14 2003-06-26 Alcon, Inc. Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma
TW593302B (en) * 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
PT1534391E (pt) * 2002-07-19 2007-05-31 Biovitrum Ab Novos derivados e piperazinilo-pirazinona para o tratamento de desordens relacionadas com o receptor 5-ht
JP2006501245A (ja) * 2002-08-30 2006-01-12 アルコン，インコーポレイテッド 置換された５−クロマン−５−イル−エチルアミン化合物および緑内障の治療のためのその使用
BR0316775A (pt) * 2002-12-13 2005-11-01 Alcon Inc Novos análogos de benzopirano e seu uso para o tratamento de glaucoma
CA2536185C (en) * 2003-08-20 2012-06-26 Santen Pharmaceutical Co., Ltd. Drug delivery system by administrating fine particles to sub-tenon
US7476687B2 (en) * 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
TW200520760A (en) * 2003-12-15 2005-07-01 Alcon Inc Substituted [1,4] oxazino [2,3-g] indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US7129257B1 (en) * 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US20050276867A1 (en) 2004-06-09 2005-12-15 Allergan, Inc. Stabilized compositions comprising a therapeutically active agent and an oxidizing preservative
US7425572B2 (en) * 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
TW200744567A (en) * 2005-09-23 2007-12-16 Alcon Inc Phenylethylamine analogs and their use for treating glaucoma
US20070293475A1 (en) * 2006-06-20 2007-12-20 Alcon Manufacturing Ltd. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
EP2119436A4 (en) 2006-10-20 2010-03-03 Ltd Liability Company Mitotech PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF EYE DISEASES
WO2008048135A1 (fr) * 2006-10-20 2008-04-24 Limited Liability Company 'mitotechnology' Composition destinée à la régénération, la stimulation de la croissance et l'adaptation de plantes à tous types de facteurs de stress
US8349902B2 (en) 2007-01-29 2013-01-08 Mitotech Sa Pharmaceutical compositions useful for preventing and treating oncological diseases
EP2145623A4 (en) * 2007-01-29 2010-10-27 Ltd Liability Company Mitotech PHARMACEUTICAL AND COSMETIC COMPOSITIONS FOR ACCELERATING THE PROCESS OF WOUND HEALING AND OTHER SURFACE INJURIES
US8679557B2 (en) * 2007-02-27 2014-03-25 Sentiss Pharma Private Limited Synergistic herbal ophthalmic formulation for lowering the intra ocular pressure in case of glaucoma
US9439916B2 (en) * 2007-04-11 2016-09-13 Mitotech Sa Composition for decelerating the aging in the organism and for extending the life time thereof and the use of said composition
US8518915B2 (en) 2007-06-29 2013-08-27 Mitotech Sa Use of mitochondrially-addressed compounds for preventing and treating cardiovascular diseases
WO2010056145A1 (ru) 2008-11-12 2010-05-20 Общество С Ограниченной Ответственностью "Митотехнология" Способ умеренного повышения протонной проводимости биологических мембран при помощи митохондриально- адресованных делокализованных катионов
MX2012005356A (es) 2009-11-13 2013-01-29 Obschestvo S Ogranichennoi Otvetstvennostyu Mitotekh Substancias farmaceuticas basadas en antioxidantes dirigidos a mitocondria.
US9320690B2 (en) 2010-12-20 2016-04-26 Colgate-Palmolive Company Gelatin encapsulated oral care composition containing hydrophilic active, hydrophobic structuring agent and oil carrier
WO2012167236A1 (en) 2011-06-03 2012-12-06 Mitotech Sa Oral formulations of mitochondrially-targeted antioxidants and their preparation and use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK166779B1 (da) * 1983-12-14 1993-07-12 Takeda Chemical Industries Ltd 1,5-benzoxatiepinderivater eller farmaceutisk acceptable salte deraf, samt farmaceutisk praeparat indeholdende en saadan forbindelse
EP0229467A1 (en) * 1985-12-10 1987-07-22 Takeda Chemical Industries, Ltd. 1,5-Benzoxathiepin derivatives, their production and use

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102548548A (zh) * 2009-06-10 2012-07-04 米拓科技有限责任公司 用于医学和兽医学的眼科药物组合物
CN102548548B (zh) * 2009-06-10 2017-09-01 米拓科技有限公司（卢森堡） 用于医学和兽医学的眼科药物组合物
CN107362157A (zh) * 2009-06-10 2017-11-21 米拓科技有限公司（卢森堡） 用于医学和兽医学的眼科药物组合物
CN107362157B (zh) * 2009-06-10 2022-08-26 米拓科技有限公司（卢森堡） 用于医学和兽医学的眼科药物组合物
CN114767688A (zh) * 2019-09-04 2022-07-22 武汉科福新药有限责任公司 透皮促渗组合物及其在噻吗洛尔制剂中的应用

Also Published As

Publication number Publication date
EP0667156B1 (en) 1997-09-10
US5538974A (en) 1996-07-23
EP0667156A1 (en) 1995-08-16
ATE157870T1 (de) 1997-09-15
CA2141176A1 (en) 1995-07-28
KR950032169A (ko) 1995-12-20
TW316235B (https=) 1997-09-21
DE69500660D1 (de) 1997-10-16
DE69500660T2 (de) 1998-02-26
ES2106573T3 (es) 1997-11-01

Similar Documents

Publication Publication Date Title
CN1116928A (zh) 眼用组合物
CN1118460C (zh) 作为5HTzc-受体拮抗剂的嘧啶衍生物
CN1304390C (zh) 新颖的γ—分泌酶抑制剂
CN1036652C (zh) 碱式季酰胺，其制备方法及其药物组合物
CN1062269C (zh) 新型(r)-5-氨甲酰基-8-氟-3-n，n-二取代氨基-3，4-二氢-2h-1-苯并吡喃
CN1073101C (zh) 取代的1,2,3,4－四氢化萘衍生物
CN1294577A (zh) 钾通道抑制剂
CN1468224A (zh) 用作α-2拮抗剂的喹啉衍生物
CN1678589A (zh) 作为药物的新氨基吲唑衍生物与含有它们的药物组合物
CN1455769A (zh) 用作β－3肾上腺素能受体激动剂的环胺磺酰胺
CN1324360A (zh) 双环氮杂环
CN1045781A (zh) N-(3-羟基-4-哌啶基)(二氢苯并呋喃，二氢-2h-苯并吡喃或二氢苯并二英)甲酰胺衍生物
CN1284948A (zh) 治疗活性化合物中的儿茶酚的吲唑生物等排物置换
CN1250652A (zh) 苯并噁嗪酮与核苷类似物的组合
CN1349524A (zh) 血管紧张肽原酶抑制剂
CN1352635A (zh) 用作mek酶抑制剂的喹啉衍生物
CN1468230A (zh) 化合物
CN1886135A (zh) 用作毒蕈碱性受体调节剂的苯基－哌嗪衍生物
CN1585752A (zh) 4,4－二氟－1,2,3,4－四氢－5h－1－苯并氮杂䓬衍生物或其盐
CN86102349A (zh) 制备n-[(4-哌啶基)烷基]取代的双环稠合的唑与噻唑胺之方法
CN1798744A (zh) 作为nmda/nr2b拮抗剂的3－氟－哌啶化合物
CN1756740A (zh) 具有2,6－二取代苯乙烯基的含氮杂环衍生物
CN1288157C (zh) 供治疗胃底松弛作用损伤的二氧杂环己烯并吡啶化合物，其制备方法和用途
CN1067985C (zh) 吲哚衍生物及含它们的药物
CN1264847C (zh) 1－氧杂－3,9－二氮杂－螺[5.5]十一－2－酮衍生物及其作为神经激肽受体拮抗剂的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination